Halozyme Therapeutics has made an unsolicited bid to acquire Evotec for 11 euros per share, totaling around 2 billion euros, aiming to enhance its strategic position in the drug industry. Bluebird bio has recorded its first revenue from its gene therapy Lyfgenia for sickle cell disease, while BeiGene has rebranded as BeOne Medicines to emphasize its oncology focus and distance itself from its Chinese roots. Adaptimmune plans to lay off a third of its workforce to save $300 million and focus on its cell therapy Tecelra, while Abeona Therapeutics awaits a decision from the FDA on its gene therapy pz-cel for a rare skin condition by April 2025.
Leerink Partners has expanded its team by hiring Jason Truman and Grant Curry as senior managing directors from Guggenheim Securities and Gordon Dyal & Co. This move is part of the firm's ongoing recruitment efforts in the health-care advisory sector.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
